Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Background & Aims Biologics are used routinely in pregnant women with inflammatory
bowel disease (IBD), but large-scale data reporting adverse pregnancy outcomes among …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Inflammatory bowel disease (IBD) has a peak age of diagnosis before the age of 35 years.
Concerns about infertility, adverse pregnancy outcomes, and heritability of IBD have …

Two new biological drugs (vedolizumab and ustekinumab) and one small molecule
(tofacitinib) have been recently approved for the treatment of inflammatory bowel disease …

Introduction: The peak age of diagnosis of inflammatory bowel disease (IBD) occurs during
childbearing years, therefore management of IBD during pregnancy is a frequent …

Background The effect of inflammatory bowel disease (IBD) on pregnancy‐related outcomes
remains unknown. Aim To determine the risk of adverse maternal, placental and obstetric …

Inflammatory bowel disease (IBD) poses complex issues in pregnancy, but with high-quality
care excellent pregnancy outcomes are achievable. In this article, we review the current …